No annual revenue total was found in RELMADA THERAPEUTICS, INC.'s SEC filings.
Relmada Therapeutics, Inc. (RLMD) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue (TTM)
$3,166
Net income (TTM)
$-49,347
Operating cash flow (TTM)
$-45.99M
+7.9% vs year-ago TTM
Free cash flow
$-209.86M
-3389.3% vs prior year
EPS
$-1.45
+45.3% vs prior year
Dividend per share
None
Shares outstanding
104.89M
+216.0% vs prior year
Net cash
—
Operating margin
-1558.7%
FY 2014
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RLMD (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Coral Gables, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1553643
- Former names
- CAMP NINE, INC. (until Jul 14, 2014)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$59.1M | -$83.9M | -$103.7M | -$161.2M | -$125.7M |
| Net income | -$57.4M | -$80.0M | -$98.8M | -$157.0M | -$125.8M |
| Diluted EPS | -$1.45 | -$2.65 | -$3.28 | -$5.30 | — |
| Operating cash flow | -$45.8M | -$51.8M | -$51.7M | -$103.8M | -$91.9M |
| Total assets | $94.0M | $45.8M | $97.6M | $152.9M | $223.3M |
| Total liabilities | $7.5M | $10.3M | $12.2M | $12.5M | $15.1M |
| Stockholders' equity | $86.5M | $35.5M | $85.4M | $140.4M | $208.3M |
| Cash and investments | $93.0M | $44.9M | $96.3M | $148.3M | $167.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Sep 8, 2026 | Sep 3, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 6, 2026 | Aug 6, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 28, 2026 | Jul 28, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
May 28, 2026 | May 27, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
May 12, 2026 | May 12, 2026 |
All 606 Relmada Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.